Heat Biologics Inc (NASDAQ:HTBX) was the target of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,007,916 shares, an increase of 52.1% from the February 15th total of 662,573 shares. Currently, 3.4% of the shares of the company are sold short. Based on an average daily volume of 2,299,772 shares, the days-to-cover ratio is presently 0.4 days.

HTBX has been the topic of several recent research reports. ValuEngine downgraded shares of Heat Biologics from a “buy” rating to a “hold” rating in a report on Tuesday, December 25th. HC Wainwright set a $6.00 price objective on shares of Heat Biologics and gave the company a “buy” rating in a report on Friday, November 16th.

Institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp bought a new stake in shares of Heat Biologics during the second quarter valued at about $111,000. Virtu Financial LLC bought a new stake in shares of Heat Biologics during the fourth quarter valued at about $55,000. Vanguard Group Inc increased its position in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 136,256 shares during the period. Vanguard Group Inc. increased its position in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 136,256 shares during the period. Finally, CVI Holdings LLC bought a new stake in shares of Heat Biologics during the fourth quarter valued at about $1,527,000. Hedge funds and other institutional investors own 16.39% of the company’s stock.

Shares of HTBX opened at $1.22 on Friday. Heat Biologics has a twelve month low of $0.95 and a twelve month high of $4.30.

WARNING: “Heat Biologics Inc (HTBX) Short Interest Up 52.1% in February” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2019/03/15/heat-biologics-inc-htbx-short-interest-up-52-1-in-february.html.

Heat Biologics Company Profile

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Featured Story: Cost of Equity For A Business, Investors

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.